Clinical trial
Study of Picibanil (OK432) Sclerotherapy in Children With Macrocystic Lymphatic…
NCT00010452 · University of Iowa, Other · Completed
Key facts
| NCT number | NCT00010452 |
|---|---|
| Title | Study of Picibanil (OK432) Sclerotherapy in Children With Macrocystic Lymphatic Malformations |
| Official title | Treatment of Cystic Hygroma (Lymphangiomas) in Children- Picibanil(OK432) Sclerotherapy-Multicenter Trial |
| Lead sponsor | University of Iowa, Other |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Lymphatic Malformations |
| Intervention type | Drug |
| Interventions | picibanil |
| Enrollment | 150 |
| Start date | Apr 1, 2000 |
| Primary completion | Jun 1, 2006 |
| Completion | Nov 1, 2007 |
| First posted | Feb 2, 2001 |
| Last update posted | Mar 25, 2015 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: